Long-term protection against carriage of hepatitis B virus after infant vaccination.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSande, Marianne A B van der
McConkey, S J
Hall, A J
Whittle, H C
MetadataShow full item record
TitleLong-term protection against carriage of hepatitis B virus after infant vaccination.
PubliekssamenvattingBACKGROUND: Carriage of hepatitis B virus (HBV) is a major risk factor for liver cirrhosis and hepatocellular carcinoma. Infant vaccination has been effective in preventing horizontal transmission during early childhood. It is unknown whether protection is maintained into early adulthood. METHODS: In 1984, early childhood vaccination was introduced in 2 rural Gambian villages. In 2003, serological assessment of 81.5% of 1,350 eligible participants 1-24 years old was done, to determine vaccine efficacy against infection and carriage. RESULTS: Overall vaccine efficacy against infection and carriage was 83.4% (95% confidence interval [CI], 79.8%-86.6%) and 96.5% (85% CI, 93.9%-98.9%), respectively. Vaccine efficacy against infection was similar when restricted to primary responders (85.3%), but a significant effect of peak antibody concentration was found. Both vaccine efficacy and levels of hepatitis B surface antibody (anti-HBs) decreased with age, resulting in a vaccine efficacy against infection and carriage among 20-24-year-old participants of 70.9% (95% CI, 60.4%-80.5%) and 91.1% (95% CI, 75.8%-100%), respectively. Fifteen years after vaccination, fewer than half of the vaccinees had detectable anti-HBs. The prevalence of carriage in the unvaccinated population was similar to the prevalence 20 years earlier. CONCLUSIONS: HBV vaccination early during life can provide long-lasting protection against carriage, despite decreasing antibody levels. The role played by subclinical boosting and the necessity of a booster need to be evaluated.
- Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages.
- Authors: Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A
- Issue date: 1995 Apr 29
- Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence.
- Authors: van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC
- Issue date: 2007 Aug 15
- Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation.
- Authors: Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, Inskip HM, George MO, Whittle HC
- Issue date: 1993 May 1
- Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program.
- Authors: Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ
- Issue date: 2014 Jan 7
- Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose.
- Authors: Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, Sidibeh M, Jatta A, Moore SE, Hall AJ, Whittle H
- Issue date: 2013